Author: Jaime Hannula

Cellular Biomedicine Group and Novartis Partner to Bring CAR-T Cancer Therapy to China

Shares of Cellular Biomedicine Group (CBMG) have resumed pre-market activity after a brief halt following the company’s announcement Thursday that it has entered into a strategic licensing and collaboration agreement with Novartis (NVS) to manufacture and supply the CAR-T cell therapy Kymriah in China. Novartis will be the the exclusive holder of the marketing license. Under the terms of the […]